Coloplast A/S Class B · OMXCOP:COLO_B
Coloplast A/S Class B — Barclays Global Healthcare Conference 2020
13 slides from Coloplast A/S Class B's conference presentation, Mar 10, 2020
Slide 1: Making it easier to get back on track
Making it easier to get back on track It took a while but now I have taken back control. I’m trying new things, pushing my limits again. Alessia Leading Value creation intimate through healthcare profitable growth Roadshow Barclays Global presentation Healthcare Conference, Miami 2020 Q1 2019/20 Mar
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Coloplast has four business areas all with global sales presence
Coloplast has four business areas all with global sales presence Group revenue 2018/19 by segment Group revenue 2018/19 by geography X = Coloplast’s global market position Emerging markets 17% Ostomy Care Continence 40% Care 36% #1 DKK DKK 17.9bn #1 Other 17.9bn European developed markets markets 59
Slide 4: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? People who have had their intestine redirected to an SenSura® Mio opening in the abdominal wall Ostomy bag Ostomy Care People in need of bladder or bowel management SpeediCath® Continence Flexible male
Slide 5: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends Drivers Limiters Earlier detection and Growing elderly Surgical and cure, eventually 1 Demographics population increases 1 medical trends reduces addressable customer base for market for Coloplast Coloplast products treatment products Ex
Slide 6: Strong market positions in Europe and great commercial potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Developed Emerging Ostomy Continence Urology Wound Care Addressable market 18-19n 13-14bn 12-13bn 22-24bn 4-5% 5-6% 3-5% 2-4% Size in DKK Growth in % Coloplast 40 - 50% 45 - 55% 20 - 25% 5 - 10% regi
Slide 7: Our LEAD20 strategy expires this year and has successfully accelerated growth
Our LEAD20 strategy expires this year and has successfully accelerated growth and long-term value creation LEAD20 strategy Long-term guidance Financial performance End of FY19/20 Organic growth, EBIT (%) & ROIC (%) Full year Quarter Revenue growth annual organic 8% 8% 7-8% 7% 7% 7–9% 4-5% market gro
Slide 8: Solid start to the year with 8% organic growth in Q1
Solid start to the year with 8% organic growth in Q1 and guidance for 2019/20 maintained Revenue growth Q1 2019/20 Highlights • Organic growth of 8% (9% reported growth in DKK) driven by solid Reported revenue (DKKm) +8% momentum across all business areas and geographies Organic growth • Solid quart
Slide 9: Solid growth across all business areas and geographical regions
Solid growth across all business areas and geographical regions Q1 19/20 revenue by business area Q1 19/20 revenue by geography Business Reported revenue Organic growth Share of organic Geographic Reported revenue Organic growth Share of organic area DKKm growth area DKKm growth Ostomy Care 1,907 9%
Slide 10: Unchanged guidance for FY 2019/20
Unchanged guidance for FY 2019/20 Guidance 2019/20 Guidance 2019/20 (DKK)* Key assumptions • Stable growth trends across regions and business areas • Up to 1% negative price pressure from reforms in France, Holland and Switzerland Sales growth 7-8% 7-8% • Approx. half of 9% price cut in Chronic Care
Slide 11: Continue to provide attractive cash returns despite large investments
Continue to provide attractive cash returns despite large investments in commercial and expansion activities Coloplast cash distribution to investors Comments • Coloplast returns excess liquidity to Dividends paid out in the year (mDKK) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) shareholders in
Slide 12: Making it easier to be yourself
Making it easier_ to be yourself Clothes are a part of my identity, so I worried about what I could wear after my operation. Today, I still dress the way I want. Coloplast Capital Market Day 2020 24 June 2020 in Copenhagen – SAVE THE DATE! The event is intended to give institutional investors and eq
Slide 13: Our mission, values and vision
Our mission Making life easier for peoplé with intimate healthcare needs Our values Closeness... to better understand. - Passion... to make a difference Respect and responsibility... to 0 guide | US: Our vision Setting the global standard for listening and responding: Coloplast Group - Ostomy Care /
Coloplast — Barclays Global Healthcare Conference 2020 on 6ix